News | March 04, 2022
USFDA refuses to grant EUA to Covaxin for padeatric use
Covaxin is not approved in the USA for any age group
Covaxin is not approved in the USA for any age group
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Serina has over 17 years of experience in the biopharmaceutical industry
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country
Subscribe To Our Newsletter & Stay Updated
